AI assistant
RENALYTIX PLC Director's Dealing 2021
7877_dirs_2021-12-09_e0b27b67-0adf-4092-aba0-bfd9497de121.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 1070V
Renalytix PLC
09 December 2021
Renalytix plc
("Renalytix" or the "Company")
Director/PDMR Dealing
New York, 9 December 2021 - Renalytix (LSE: RENX) announces that it has been advised of the purchase of 4,805 American Depositary Shares ("ADS") by certain members of the Board of Directors and senior management, in open market purchases using personal funds, each representing two ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares").
Director Purchases
The following members of the Board of Directors and senior management have purchased ADS' in the company, in the amounts set out below:
| Director | ADS' Purchased | Aggregate Price per ADS | Current Ordinary Shares Held | Holding post Purchase | % of Current Issued Share Capital |
| James McCullough (CEO) | 1,003 | $15.53 | 2,742,010 | 2,744,016 | 3.8% |
| O. James Sterling (CFO) | 802 | $15.00 | 1,811,236 | 1,812,840 | 2.5% |
| Ann Berman (NED) | 3,000 | $15.00 | - | 6,000 | 0.01% |
For further information, please contact:
| Renalytix plc | www.renalytix.com | |
| James McCullough, CEO | Via Walbrook PR | |
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
| Alex Price / Nicholas Moore | ||
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
| Gary Clarence / Daniel Adams | ||
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |
| Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | |
About KidneyIntelX
KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
The information contained in this notification is disclosed in accordance with the requirements of MAR.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | James McCullough | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Renalytix plc | |
| b) | Legal Entity Identifier | 213800NTOH3FK3WER551 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
ADS', each ADS representing two Ordinary Shares of £0.0025 each. US75973T1016 |
|
| b) | Nature of the transaction | Purchase of ADS' | |
| c) | Currency | US Dollar | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $15.10 | 120 ADS (representing 240 Ordinary Shares) | ||
| $15.00 | 33 ADS (representing 66 Ordinary Shares) | ||
| $15.05 | 150 ADS (representing 300 Ordinary Shares) | ||
| $16.05 | 200 ADS (representing 400 Ordinary Shares) | ||
| $15.60 | 500 ADS (representing 1000 Ordinary Shares) | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
1,003 ADS (representing 2,006 Ordinary Shares) $15.53 $15,574.50 |
|
| f) | Date of the transaction | 9 December 2021 | |
| g) | Place of the transaction | Nasdaq Stock Exchange |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | O. James Sterling | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Renalytix plc | |
| b) | Legal Entity Identifier | 213800NTOH3FK3WER551 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
ADS', each ADS representing two Ordinary Shares of £0.0025 each. US75973T1016 |
|
| b) | Nature of the transaction | Purchase of ADS' | |
| c) | Currency | US Dollar | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $15.00 | 802 ADS (representing 1,604 Ordinary Shares) | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
802 ADS (representing 1,604 Ordinary Shares) $15.00 $12,030.00 |
|
| f) | Date of the transaction | 9 December 2021 | |
| g) | Place of the transaction | Nasdaq Stock Exchange |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Ann Berman | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Renalytix plc | |
| b) | Legal Entity Identifier | 213800NTOH3FK3WER551 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
ADS', each ADS representing two Ordinary Shares of £0.0025 each. US75973T1016 |
|
| b) | Nature of the transaction | Purchase of ADS' | |
| c) | Currency | US Dollar | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $15.00 | 3,000 ADS (representing 6,000 Ordinary Shares) | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
3,000 ADS (representing 6,000 Ordinary Shares) $15.00 $45,000.00 |
|
| f) | Date of the transaction | 9 December 2021 | |
| g) | Place of the transaction | Nasdaq Stock Exchange |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEAKANELAFFEA